Review
Oncology
Alice Indini, Olga Nigro, Csongor Gyorgy Lengyel, Michele Ghidini, Angelica Petrillo, Salvatore Lopez, Francesco Raspagliesi, Dario Trapani, Shelize Khakoo, Giorgio Bogani
Summary: Patients with platinum-resistant ovarian cancer have a poor prognosis with limited treatment options. While single-agent immunotherapy has shown disappointing results, combining immunotherapy with target therapies like PARP inhibitors and TKIs appears promising. Ongoing trials are evaluating these combination strategies to assess their impact and cost-effectiveness.
Article
Oncology
Michal Mleko, Elzbieta Pluta, Kazimierz Pitynski, Maciej Bodzek, Andrzej Kalamacki, Dorota Kiprian, Tomasz Banas
Summary: Epithelial ovarian cancer is the deadliest gynaecological malignancy, and cytoreductive surgery followed by adjuvant taxane-platinum-based chemotherapy is the main therapy for this cancer. Systemic inflammatory response plays a dual role in the pathophysiology of neoplastic diseases, predicting poor survival. However, there are only few studies on changes in inflammatory markers during anti-cancer treatment. This study aimed to investigate trends in changes in inflammatory markers in women with ovarian cancer receiving standard first-line adjuvant chemotherapy.
Article
Oncology
Hiroki Nasu, Shin Nishio, Jongmyung Park, Teruyuki Yoshimitsu, Ken Matsukuma, Kazuto Tasaki, Takahiro Katsuda, Atsumu Terada, Naotake Tsuda, Kimio Ushijima
Summary: This study evaluated the efficacy and safety of gemcitabine and carboplatin with or without bevacizumab in patients with platinum-resistant ovarian cancer (PROC). The results showed that GC +/- B may be an effective and safe treatment alternative for PROC, especially for patients with a platinum-free interval of 3-6 months.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ozge Esim, Canan Hascicek, Mustafa Emre Gedik, Gurcan Gunaydin, Ayse Lale Dogan
Summary: The developed nanoformulation, co-loaded with carboplatin and decitabine, effectively modulated platinum resistance and exhibited cytotoxic and apoptosis-inducing effects in ovarian cancer cells. The nanoformulation also reactivated the MLH1 gene in platinum-resistant ovarian cancer cells, enhancing drug sensitivity.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
(2022)
Article
Oncology
Juran Kralj, Margareta Pernar Kovac, Sanja Dabelic, Darija Stupin Polancec, Thorsten Wachtmeister, Karl Koehrer, Anamaria Brozovic
Summary: A novel OC cell model was established, and two transcriptome analysis approaches identified TMEM200A and PRKAR1B as important genes in carboplatin resistance and metastasis, with high predictive and prognostic values for OC patients. Compared to parental cells, carboplatin-resistant cells showed increased sensitivity to PI3K/Akt/mTOR pathway inhibitors and enhanced sensitivity to carboplatin when treated with a transcription inhibitor.
BRITISH JOURNAL OF CANCER
(2023)
Review
Oncology
Siyu Li, Tao Wang, Xichang Fei, Mingjun Zhang
Summary: Platinum-resistant ovarian cancer is a deadly cancer with a poor prognosis, and ATR inhibitors have shown promising results in its treatment.
Article
Obstetrics & Gynecology
Woo Yeon Hwang, Minjung Lee, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Ju-Hyun Kim
Summary: In patients with epithelial ovarian cancer, prior use of carboplatin was identified as an independent risk factor for carboplatin-related hypersensitive reactions, while hypersensitivity to carboplatin did not impact overall survival.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2022)
Review
Biotechnology & Applied Microbiology
Ahmad Awada, Sarfraz Ahmad, Nathalie D. McKenzie, Robert W. Holloway
Summary: Epithelial ovarian cancer is the most lethal gynecologic cancer and current treatment strategies of surgery plus chemotherapy have limited effectiveness in preventing recurrence. Immunotherapy has shown limited activity in EOC due to its unique genomics and micro-immune environment, necessitating further research into new strategies for its use.
ONCOTARGETS AND THERAPY
(2022)
Article
Oncology
John B. Liao, William R. Gwin, Renata R. Urban, Katie M. Hitchcock-Bernhardt, Andrew L. Coveler, Doreen M. Higgins, Jennifer S. Childs, Hania N. Shakalia, Ron E. Swensen, Sasha E. Stanton, Anna Tinker, Tanya A. Wahl, Richard G. Ancheta, Kathryn F. McGonigle, James Y. Dai, Mary L. Disis, Barbara A. Goff
Summary: The study evaluated the activity and safety of pembrolizumab with carboplatin in recurrent platinum-resistant ovarian cancer, showing that this treatment approach had modest activity and good tolerability. A ratio of peripheral T-cell exhaustion to radiographic tumor burden may help identify patients who are more likely to benefit from this chemoimmunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Platinum-resistant ovarian cancer is associated with poor prognosis and limited treatment options. Combination treatment with immunotherapy, anti-angiogenic therapy, and chemotherapy can significantly extend progression-free survival in these patients.
Article
Oncology
Rachel E. Kinney, Suresh Nair, Christine H. Kim, M. Bijoy Thomas, Martin DelaTorre
Summary: Ovarian cancer is a common gynecologic cancer in the US, and platinum-resistant disease has a poor prognosis. This study suggests that treatment with immunotherapy followed by anti-angiogenic therapy and chemotherapy can improve survival in patients with platinum-resistant ovarian cancer. The experience of three patients showed significantly longer progression-free survival compared to previous averages.
Article
Oncology
Michelle McMullen, Ainhoa Madariaga, Stephanie Lheureux
Summary: Platinum drugs are crucial in ovarian cancer treatment, but resistance is a major challenge, with complex mechanisms involving both intracellular and microenvironment factors. Clinical trials are essential for improving outcomes, and future research should focus on understanding the biology of the disease and enhancing quality of life and survival for patients.
SEMINARS IN CANCER BIOLOGY
(2021)
Article
Oncology
Claudia Marchetti, Riccardo Tudisco, Vanda Salutari, Antonella Pietragalla, Giovanni Scambia, Anna Fagotti
Summary: This study aims to evaluate whether the combination of olaparib with standard chemotherapy in the neoadjuvant setting can improve tumor response, with the hypothesis that adding a poly adenosine diphosphate-ribose polymerase inhibitor will achieve a higher response rate in BRCA mutated patients. The trial will enroll 35 eligible patients with III-IV stage ovarian, peritoneal, or fallopian tube cancer for evaluation.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Maria Rubinstein, Sherry Shen, Bradley J. Monk, David S. P. Tan, Angelica Nogueira-Rodrigues, Daisuke Aoki, Jalid Sehouli, Vicky Makker
Summary: Incidence and mortality of endometrial cancer are increasing among all ethnic groups. Carboplatin plus paclitaxel is the frontline treatment, but subsequent traditional cytotoxic chemotherapy is challenging. Molecular characterization has led to the development of precision immunotherapies and targeted therapies. The applicability of platinum rechallenge is subjective and limited by small retrospective studies.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Justin W. Gorski, Zhuwei Zhang, J. Robert McCorkle, Jodi M. DeJohn, Chi Wang, Rachel W. Miller, Holly H. Gallion, Charles S. Dietrich, Frederick R. Ueland, Jill M. Kolesar
Summary: The development of patient-derived tumor organoids from epithelial ovarian cancer has the potential to contribute significantly to precision medicine by testing chemotherapy sensitivity and investigating genetic drivers of drug resistance. This study identified one organoid line resistant to carboplatin, leading to a shorter progression-free survival and platinum-resistant recurrence. Gene expression analysis revealed interconnected pathways related to NF-kB, cellular differentiation, and B-cell receptor signaling in the context of carboplatin resistance.
Review
Oncology
Nicole Birrer, Carolina Chinchilla, Marcela Del Carmen, Don S. Dizon
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2018)
Editorial Material
Oncology
Mina S. Sedrak, Don S. Dizon, Patricia F. Anderson, Michael J. Fisch, David L. Graham, Matthew S. Katz, Jennifer C. Kesselheim, Robert S. Miller, Michael A. Thompson, Audun Utengen, Deanna J. Attai
Article
Oncology
Sarah E. Pesek, Heather M. King, Susan Koelliker, Christina Raker, David Edmonson, Don S. Dizon, Jennifer Gass
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
(2018)
Article
Oncology
Areej El-Jawahri, Sarah R. Fishman, Julie Vanderklish, Don S. Dizon, Nicole Pensak, Lara Traeger, Joseph A. Greer, Elyse R. Park, Netana Markovitz, Lauren Waldman, Chrisa Hunnewell, Meredith Saylor, Jessica Driscoll, Zhigang Li, Thomas R. Spitzer, Steven McAfee, Yi-Bin Chen, Jennifer S. Temel
Article
Oncology
Carol Aghajanian, Virginia Filiaci, Don S. Dizon, Jay W. Carlson, Matthew A. Powell, Angeles Alvarez Secord, Krishnansu S. Tewari, David P. Bender, David M. O'Malley, Ashley Stuckey, Jianjiong Gao, Fanny Dao, Robert A. Soslow, Heather A. Lankes, Kathleen Moore, Douglas A. Levine
GYNECOLOGIC ONCOLOGY
(2018)
Meeting Abstract
Oncology
Belle Hadewijch de Rooij, Elyse R. Park, Giselle Katiria Perez, Julia Rabin, Katharine M. Quain, Don S. Dizon, Kathryn E. Post, Garrett Chinn, Allison McDonough, Rachel Jimenez, Lonneke V. van de Poll-Franse, Jeffrey M. Peppercorn
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Belle Hadewijch de Rooij, Teresa Hagan, Kathryn E. Post, Jane M. Flanagan, Jeffrey M. Peppercorn, Don S. Dizon
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Article
Oncology
Don S. Dizon, Dora Dias-Santagata, Amy Bregar, Laura Sullivan, Jennifer Filipi, Elizabeth DiTavi, Lucy Miller, Leif Ellisen, Michael Birrer, Marcela DelCarmen
Meeting Abstract
Oncology
Jeffrey M. Peppercorn, Katharine M. Quain, Karen Sepucha, Don S. Dizon, Beverly Moy, Laura Spring, Therese Marie Mulvey, Jennifer Adrienne Shin, Giselle Katiria Perez
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Meeting Abstract
Oncology
Emeline Aviki, Marina Stasenko, Sarah E. Dilley, William P. Tew, Don S. Dizon, Peter Bach, Carol L. Brown
JOURNAL OF CLINICAL ONCOLOGY
(2018)
Review
Surgery
Mary Lopresti, Tina Rizack, Don S. Dizon
Meeting Abstract
Hematology
Areej R. El-Jawahri, Sarah Fishman, Julie Vanderklish, Lara Traeger, Don Dizon, Thomas R. Spitzer, Steven L. McAfee, Zachariah DeFilipp, Yi-Bin Chen, Jennifer Temel
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2018)
Article
Oncology
Eleonora P. Preti, Fabio Landoni, Nicoletta Colombo, Don S. Dizon
Letter
Oncology
C. Dittrich, F. Stiefel, A. Kiss, D. S. Dizon
ANNALS OF ONCOLOGY
(2017)
Article
Oncology
Jennifer Y. Wo, Lorraine C. Drapek, Andrzej Niemierko, Brenda Silvia, Bridget N. Noe, Andrea L. Russo, David T. Miyamoto, Theodore S. Hong, Jason A. Efstathiou, Anthony L. Zietman, Don S. Dizon
PRACTICAL RADIATION ONCOLOGY
(2018)
Article
Oncology
Dimitrios Nasioudis, Stefan Gysler, Nawar Latif, Lory Cory, Robert L. Giuntoli II, Sarah H. Kim, Fiona Simpkins, Lainie Martin, Emily M. Ko
Summary: The prevalence of ERBB2 gene amplification was investigated among patients with gynecologic malignancies. The study found that ERBB2 amplification is frequently encountered in uterine serous carcinoma and mucinous ovarian carcinoma, but less common in endometrioid endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2024)